| Drug class | Considerations |
BTK inhibitor: - Ibrutinib
- Acalabrutinib
- Zanubrutinib
- Pirtobrutinib
| - Oral medication
- Administered as continuous therapy
- Increases the risk for bleeding, atrial fibrillation, hypertension
- Avoid or dose reduce with strong CYP3A inhibitors/inducers
|
| BCL2 inhibitor: | - Oral medication
- Administered as continuous therapy (single agent) or for a fixed duration (as combination therapy)
- Monitor for tumor lysis syndrome
- Avoid nephrotoxic drugs and moderate or strong CYP3A inducers; avoid or dose reduce with CYP3A inhibitors
|
| PI3K inhibitor: | - Oral medication
- Administered as continuous therapy as a single agent (duvelisib) or in combination with rituximab (idelalisib)
- Fatal and/or serious toxicities can be seen, including opportunistic infections, diarrhea or colitis, cutaneous reactions, and pneumonitis
- Avoid or dose reduce with strong CYP3A inhibitors/inducers; inhibits CYP3A
|
Anti-CD20 monoclonal antibody: - Rituximab
- Obinutuzumab
- Ofatumumab
| - Intravenous medication
- Usually administered in combination with other agents
- Infusion reactions, infections related to immunosuppression, hepatitis B reactivation, rare cases of progressive multifocal leukoencephalopathy
|
